MAP Kinase Signaling
| CSTコード |
包装 |
希望納入価格（円） |
国内在庫  |
ご登録代理店情報 カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #1245 | 100 μg | 16,000 | |
|
p44/42 MAPK (Erk1/2)抗体製品一覧
| 使用目的 | |
| p44/42 MAPK (L34F12) Mouse mAb （#4696）の反応をブロックし、抗体の反応特異性を確認するために使用 |
IHC-P (paraffin)
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using p44/42 MAPK (Erk1/2) (L34F12) Mouse mAb #4696 in the presence of control peptide (left) or p44/42 MAPK (Erk1/2) Blocking Peptide (#4696 Specific) (right).
Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines (1-3) and is an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family as well as Mos and Tpl2/Cot. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors such as U0126 and PD98059.
-
Roux, P.P. and Blenis, J. (2004)
Microbiol Mol Biol Rev
68, 320-44.
-
Baccarini, M. (2005)
FEBS Lett
579, 3271-7.
-
Meloche, S. and Pouysségur, J. (2007)
Oncogene
26, 3227-39.
-
Roberts, P.J. and Der, C.J. (2007)
Oncogene
26, 3291-310.
-
Rubinfeld, H. and Seger, R. (2005)
Mol Biotechnol
31, 151-74.
-
Murphy, L.O. and Blenis, J. (2006)
Trends Biochem Sci
31, 268-75.
-
Dalby, K.N. et al. (1998)
J Biol Chem
273, 1496-505.
-
Marais, R. et al. (1993)
Cell
73, 381-93.
-
Kortenjann, M. et al. (1994)
Mol Cell Biol
14, 4815-24.
-
Owens, D.M. and Keyse, S.M. (2007)
Oncogene
26, 3203-13.
